Related Experiment Videos
Clinical experience with cardiac amyloidosis
Ann Goeminne1, Luc Missault, Frank Bauwens
1Departments of Cardiology, St. Jan Hospital, Brugge, Belgium.
Acta Cardiologica
|April 29, 2003
Summary
Acquired cardiac amyloidosis, a serious heart condition, has a poor prognosis. Most patients diagnosed with heart failure due to acquired amyloidosis die within a year, even with optimal treatment.
Area of Science:
- Cardiology
- Systemic Diseases
- Amyloidosis Research
Background:
- Amyloidosis is a systemic disease that can significantly impact cardiac function.
- Cardiac involvement in amyloidosis often leads to heart failure.
- Understanding the prognosis of cardiac amyloidosis is crucial for patient management.
Purpose of the Study:
- To retrospectively analyze patients with major cardiac amyloidosis.
- To evaluate the clinical characteristics, diagnostic work-up, and treatment outcomes.
- To determine the prognosis of acquired cardiac amyloidosis.
Main Methods:
- Retrospective study of eight patients diagnosed with cardiac amyloidosis between 1997 and 2000.
- Analysis of clinical, electrocardiographic, and echocardiographic data.
- Review of treatment modalities for heart failure.
Main Results:
- All eight patients presented with heart failure due to cardiac amyloidosis.
- Seven of eight patients with acquired amyloidosis (AL and AA types) died within one year.
- Death resulted from intractable cardiac failure, including systolic and diastolic left ventricular dysfunction.
- One patient with hereditary amyloidosis survived after liver transplantation.
Conclusions:
- Acquired cardiac amyloidosis carries an ominous prognosis.
- Optimal medical treatment for heart failure did not improve survival rates.
- Advanced disease stage at presentation likely contributes to the poor prognosis.